HDAC3 regulates DNMT1 expression in multiple myeloma: therapeutic implications.
T Harada1, H Ohguchi1, Y Grondin2
1Jerome Lipper Multiple Myeloma Center, Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.
Leukemia
|May 12, 2017
Summary
Targeting histone deacetylase 3 (HDAC3) and DNA methyltransferase 1 (DNMT1) simultaneously shows promise for treating multiple myeloma (MM). This combination therapy downregulates cancer cell proliferation and induces apoptosis, offering a new therapeutic strategy.
Area of Science:
- Oncology
- Epigenetics
- Molecular Biology
Background:
- Histone deacetylases (HDACs) are therapeutic targets in cancer, including multiple myeloma (MM).
- Non-selective HDAC inhibitors have shown efficacy but cause side effects.
- Selective HDAC inhibition may offer improved therapeutic outcomes.
Purpose of the Study:
- To investigate the role of HDAC3 in MM cell proliferation.
- To evaluate the efficacy of combined HDAC3 and DNA methyltransferase 1 (DNMT1) inhibition in MM.
Main Methods:
- Genetic knockdown of HDAC3, HDAC1, and HDAC2.
- Treatment with selective HDAC3 inhibitor (BG45) and DNMT1 inhibitor (5-azacytidine, AZA).
- Assessment of DNMT1 expression, c-Myc degradation, DNMT1 stability, cell proliferation, apoptosis, and in vivo efficacy in a murine xenograft model.
Main Results:
- HDAC3 inhibition, but not HDAC1 or HDAC2, downregulates DNMT1 expression and inhibits MM cell proliferation.
- HDAC3 inhibition leads to c-Myc degradation and DNMT1 hyperacetylation, reducing DNMT1 stability.
- Combined BG45 and AZA treatment synergistically inhibits MM cell growth and induces apoptosis in vitro and in vivo.
Conclusions:
- HDAC3 inhibition plays a critical role in regulating DNMT1 expression and MM cell proliferation.
- Combination therapy with an HDAC3 inhibitor and a DNMT1 inhibitor demonstrates significant anti-MM activity.
- This combination strategy warrants further investigation for improving MM patient outcomes.
